Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Digital Health Roundup: Digital Therapeutics, Restoring Function, Deals, Investing And Lobbying

Executive Summary

In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.

You may also be interested in...



Playing Big: Akili To Be Bought By Chamath Palihapitiya’s SPAC In $1Bn Deal

Akili Interactive, which developed a video game to treat ADHD, will go public with one of Palihapitiya’s blank-check companies. The proceeds will be used to launch the FDA-cleared EndeavorRx digital therapeutics.

Minute Insight: Agendia Collaborates With Illumina And Brazilian Health Care Providers

The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.

Right To Repair Proponents Gearing Up To Fight In State Legislatures Again

Groups advocating to force medtech manufacturers to provide tools and manuals to service their products are renewing efforts in state legislatures despite recent losses.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144985

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel